Wongsrichanalai C, Webster H K, Wimonwattrawatee T, Sookto P, Chuanak N, Thimasarn K, Wernsdorfer W H
Department of Immunology and Biochemistry, Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand.
Am J Trop Med Hyg. 1992 Jul;47(1):112-6. doi: 10.4269/ajtmh.1992.47.112.
Mefloquine was introduced into Thailand in 1985 for the treatment of Plasmodium falciparum infection. Recently, clinical failure of mefloquine was observed in southeastern Thailand, where an epidemic of falciparum malaria occurred. Beginning in 1984 and continuing until 1989, in vitro monitoring of P. falciparum isolates from Borai, a border district in the southeastern part of the country, showed a progressive decrease in mefloquine sensitivity until 1989; in 1990, the degree and prevalence of resistance accelerated. A similar pattern of resistance was observed for halofantrine, an antimalarial drug not yet commercially available in Thailand. In vitro sensitivity patterns of mefloquine and halofantrine elsewhere in the country remained relatively unchanged. These observations suggest a serious deterioration in available drugs for the treatment of falciparum malaria in southeastern Thailand that is predicted to spread throughout the country and Southeast Asia.
甲氟喹于1985年引入泰国用于治疗恶性疟原虫感染。最近,在泰国东南部观察到甲氟喹临床治疗失败,该地区曾发生恶性疟流行。从1984年开始并持续到1989年,对该国东南部边境地区博莱的恶性疟原虫分离株进行体外监测,结果显示直到1989年甲氟喹敏感性呈逐渐下降趋势;1990年,耐药程度和流行率加速上升。对于卤泛群(一种在泰国尚未商业化的抗疟药物)也观察到类似的耐药模式。该国其他地区甲氟喹和卤泛群的体外敏感性模式相对保持不变。这些观察结果表明,泰国东南部用于治疗恶性疟的现有药物严重恶化,预计将蔓延至全国及东南亚地区。